temozolomide has been researched along with Anemia, Hypoplastic in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | 7.76 | Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| "We report the case of a 30-year-old woman with glioblastoma multiforme (GBM) treated with surgery followed by concomitant Temozolomide (TMZ) and external beam radiation, which she tolerated well without any interruptions." | 7.74 | Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. ( Gujral, S; Jalali, R; Menon, H; Singh, P, 2007) |
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 5.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| "Temozolomide (TMZ) is an oral alkylating agent principally indicated for neurological malignancies including glioblastoma (GBM) and astrocytoma." | 5.12 | Temozolomide-induced aplastic anaemia: Case report and review of the literature. ( Gilbar, PJ; Mangos, HM; Pokharel, K, 2021) |
| "Temozolomide (TMZ) is, in combination with radiotherapy (RT), the treatment of choice for glioblastoma multiforme." | 3.83 | Persistent bone marrow depression following short-term treatment with temozolomide. ( Brandal, P; Johannesen, TB; Tjønnfjord, GE; Vandraas, K, 2016) |
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | 3.76 | Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| "Radiotherapy (RT) and concomitant/adjuvant therapy with temozolomide (Temodar) is a common treatment regimen for children and adults with glioma." | 3.75 | Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. ( Broniscer, A; Ellison, D; Kasow, K; Morris, EB; Reiss, U, 2009) |
| "A 65-year-old female patient with glioblastoma multiforme (GBM) developed aplastic anemia following treatment with temozolomide." | 3.75 | A rare case of aplastic anemia caused by temozolomide. ( Eichinger, JB; George, BJ; Richard, TJ, 2009) |
| "We report the case of a 30-year-old woman with glioblastoma multiforme (GBM) treated with surgery followed by concomitant Temozolomide (TMZ) and external beam radiation, which she tolerated well without any interruptions." | 3.74 | Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. ( Gujral, S; Jalali, R; Menon, H; Singh, P, 2007) |
| "Temozolomide-induced aplastic anemia (TIAA) is a rare but highly challenging complication of temozolomide (TMZ) therapy." | 1.72 | Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. ( Al-Samkari, H; Forst, DA; Park, AK; Waheed, A, 2022) |
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 1.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Park, AK | 1 |
| Waheed, A | 1 |
| Forst, DA | 1 |
| Al-Samkari, H | 1 |
| Gilbar, PJ | 1 |
| Pokharel, K | 1 |
| Mangos, HM | 1 |
| Batalini, F | 1 |
| Kaufmann, MR | 1 |
| Aleixo, GF | 1 |
| Drews, R | 1 |
| Dixit, S | 1 |
| Hingorani, M | 1 |
| Allgar, V | 1 |
| Kourelis, TV | 1 |
| Buckner, JC | 1 |
| Gangat, N | 1 |
| Patnaik, MM | 1 |
| Vandraas, K | 1 |
| Tjønnfjord, GE | 1 |
| Johannesen, TB | 1 |
| Brandal, P | 1 |
| Morris, EB | 1 |
| Kasow, K | 1 |
| Reiss, U | 1 |
| Ellison, D | 1 |
| Broniscer, A | 1 |
| George, BJ | 1 |
| Eichinger, JB | 1 |
| Richard, TJ | 1 |
| Kopecký, J | 1 |
| Priester, P | 1 |
| Slovácek, L | 1 |
| Petera, J | 1 |
| Kopecký, O | 1 |
| Macingova, Z | 1 |
| Villano, JL | 1 |
| Collins, CA | 1 |
| Manasanch, EE | 1 |
| Ramaprasad, C | 1 |
| van Besien, K | 1 |
| Jalali, R | 1 |
| Singh, P | 1 |
| Menon, H | 1 |
| Gujral, S | 1 |
1 review available for temozolomide and Anemia, Hypoplastic
| Article | Year |
|---|---|
Temozolomide-induced aplastic anaemia: Case report and review of the literature.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Gr | 2021 |
10 other studies available for temozolomide and Anemia, Hypoplastic
| Article | Year |
|---|---|
Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.
Topics: Anemia, Aplastic; Central Nervous System Neoplasms; Humans; Prognosis; Receptors, Thrombopoietin; Re | 2022 |
Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.
Topics: Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Fata | 2019 |
An analysis of temozolomide-related adverse drug reactions reported to the medicines and healthcare products regulatory agency through the yellow card scheme aiming to characterise idiosyncratic profound bone marrow suppression tantamount to aplastic anae
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anemia, Aplastic; Antineoplastic A | 2014 |
Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marr | 2015 |
Persistent bone marrow depression following short-term treatment with temozolomide.
Topics: Aged; Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Brain Neoplasms; Dacarb | 2016 |
Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Dacarb | 2009 |
A rare case of aplastic anemia caused by temozolomide.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Fema | 2009 |
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Dea | 2010 |
Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Outcome; Glioblastoma; Hemat | 2006 |
Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Topics: Adult; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Marrow; Brain Neo | 2007 |